The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.